Eli Lilly to Expand Facility to Meet Demand for Diabetes, Obesity Treatments

By Sabela Ojea

Eli Lilly said it would invest $3 billion to expand a recently acquired manufacturing facility to meet growing demand for its diabetes and weight-loss medicines.

The drugmaker said the Kenosha County, Wis., plant expansion would extend the reach of its injectable-product manufacturing and add 750 jobs. The facility already employs around 100 people.

Overall, the expanded facility would focus on manufacturing injectable medicines, device assembly and packaging for medicines across multiple therapeutic areas, the Indianapolis company said.

The decision comes months after Lilly resolved shortages for its weight-loss and diabetes drugs, Zepbound and Mounjaro. Lilly's rival, Novo Nordisk, has been expanding its production capacity to resolve shortages.

Write to Sabela Ojea at [e-mail]

(END) Dow Jones Newswires

12-05-24 1611ET